c-RET
c-RET inhibitors target the RET (Rearranged during Transfection) proto-oncogene, which encodes a receptor tyrosine kinase involved in cell growth, differentiation, and survival. Abnormal activation of RET signaling can lead to uncontrolled cell proliferation and resistance to apoptosis, contributing to the development of cancers such as medullary thyroid carcinoma and non-small cell lung cancer. Inhibiting c-RET can induce apoptosis in cancer cells and is a promising approach in targeted cancer therapy. At CymitQuimica, we offer a variety of high-quality c-RET inhibitors to support your research in oncology, signal transduction, and apoptosis.
Found 61 products of "c-RET"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
BT-13
CAS:BT-13 activates RET receptor without GFLs, fostering sensory neuron neurite growth in vitro.Formula:C23H27F4N3O4SPurity:99.23%Color and Shape:SolidMolecular weight:517.54Ref: TM-T10624
1mg43.00€2mg57.00€5mg96.00€10mg134.00€25mg220.00€50mg329.00€100mg470.00€1mL*10mM (DMSO)97.00€RET ligand-3
RETligand-3 is the ligand for PROTAC QZ2135, which targets RET.Formula:C38H42N10O3Color and Shape:SolidMolecular weight:686.81QZ2135
QZ2135 (compound 20) is a PROTAC degrader that specifically targets RET and exhibits antitumor activity in vivo within a Ba/F3-KIF5B-RET-G810C xenograft mouse model. The compound demonstrates degradation activity with DC50 values of 4.7 nM (WT), 17.2 nM (V804M), and 73.8 nM (G810C) when targeting KIF5B-RET. QZ2135 is composed of the target protein ligand (red part) RETligand-3, the E3 ligase ligand (blue part) Lenalidomide-F, and the PROTAC Linker (black part) 7-Iodohept-1-yne, wherein the target protein ligand combined with the linker forms the conjugate RETLigand-Linker Conjugate-1.Formula:C53H54N12O4Color and Shape:SolidMolecular weight:923.07Cofetuzumab
CAS:Cofetuzumab (PF-06523435) is a antibody targeting protein tyrosine kinase 7 (PTK7), which can be used to synthesize ADC compounds like cofetuzumab pelidotin.Purity:>95%Color and Shape:LiquidPLM-101
PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.Formula:C22H22FN5O2Color and Shape:SolidMolecular weight:407.44RET-IN-28
CAS:RET-IN-28 (Compound 16) is an inhibitor of RET (a transmembrane receptor tyrosine kinase). It specifically inhibits the activity of a mutant RET enzyme (RET-V804M) and is utilized in cancer research.Formula:C26H29N9Color and Shape:SolidMolecular weight:467.57RET-IN-4
CAS:RET-IN-4: Oral RET inhibitor, IC50 ~1 nM for variants. Selective over JAK2/FLT3. Potent anticancer use.Formula:C27H31FN10O2Color and Shape:SolidMolecular weight:546.611RET-IN-26
RET-IN-26 (compound D5) is a kinase inhibitor that selectively targets the RET protein with an IC50 value of 0.33 μM [1].Color and Shape:Odour SolidZeteletinib hemiadipate
CAS:Zeteletinib hemiadipate (BOS-172738; DS-5010) is an oral RET kinase blocker with nanomolar potency and strong anti-tumor properties.Formula:C56H56F6N8O12Color and Shape:SolidMolecular weight:1147.098RET Ligand-Linker Conjugate-1
RET Ligand-Linker Conjugate-1 consists of a complex formed by a RET ligand and a linker, which can be utilized in the synthesis of QZ2135.Formula:C40H44N10OColor and Shape:SolidMolecular weight:680.84Compound TPX-0046
CAS:Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.Formula:C21H21FN6O3Purity:99.94%Color and Shape:SoildMolecular weight:424.43YW-N-7 TFA
YW-N-7 (TFA) is a PROTAC designed to target, inhibit, and degrade RET kinase, demonstrating a DC50 of 88 nM. It exhibits antitumor activity in xenograft mouse models driven by KIF5B-RET, making it a valuable compound for cancer research.Formula:C58H63F3N12O9Color and Shape:SolidMolecular weight:1129.19BT44
CAS:BT44, a potent second-gen GDNF mimetic, is a lead for treating neurodegeneration.Formula:C28H27F4N3O4SPurity:99.87%Color and Shape:SoildMolecular weight:577.59Ref: TM-T67733
1mg74.00€5mg160.00€10mg235.00€25mg424.00€50mg635.00€100mg924.00€1mL*10mM (DMSO)188.00€AD57 (hydrochloride)
CAS:AD57, a polypharmacological agent, blocks RET kinase (IC50: 2 nM), disrupts related kinases, and hinders cancerous activities like invasion and proliferation.Formula:C22H21ClF3N7OPurity:98%Color and Shape:SolidMolecular weight:491.9RET-IN-29
RET-IN-29 (Compound 8W) is a selective RET kinase inhibitor. It demonstrates inhibitory effects on BaF3 cells with the CCDC6-RETV804M mutation, with an IC50 of 0.715 μM. RET-IN-29 shows potential for research in non-small cell lung cancer (NSCLC).Formula:C22H22N6OColor and Shape:SolidMolecular weight:386.45RET ligand-1
CAS:RETligand-1 is a target protein ligand that specifically interacts with RET and can be utilized in the synthesis of the PROTAC LDD39.Formula:C28H24F2N6O3Color and Shape:SolidMolecular weight:530.525CDD-2807
CDD-2807 is a serine/threonine kinase 33 (STK33) inhibitor with an IC50 of 9.2 nM. In mice, CDD-2807 demonstrates no significant toxicity and can cross the blood-testis barrier without accumulating in the brain. It offers reversible contraceptive effects, indicating potential for development as a male contraceptive.Formula:C29H26N4OMolecular weight:446.21066trans-Pralsetinib
CAS:trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET).Formula:C27H32FN9O2Purity:98%Color and Shape:SolidMolecular weight:533.6Pralsetinib
CAS:Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918TFormula:C27H32FN9O2Purity:97.88% - 99.8%Color and Shape:SolidMolecular weight:533.6Ref: TM-TQ0277
1mg43.00€5mg103.00€10mg145.00€25mg283.00€50mg439.00€100mg660.00€1mL*10mM (DMSO)120.00€WHI-P180
CAS:WHI-P180 (Janex 3) is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.Formula:C16H15N3O3Purity:99.21%Color and Shape:SolidMolecular weight:297.31
